Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Micha, Ipek, Rojda, Homola, György A., Rovituso, Damiano M., Schampel, Andrea, Kleinschnitz, Christoph, Kuerten, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086993/
https://www.ncbi.nlm.nih.gov/pubmed/30098594
http://dx.doi.org/10.1186/s12974-018-1263-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086993/
https://www.ncbi.nlm.nih.gov/pubmed/30098594
http://dx.doi.org/10.1186/s12974-018-1263-9

Ejemplares similares